ESPOCH Congresses: The Ecuadorian Journal of S.T.E.A.M.

ISSN: 2789-5009

Leading Ecuadorian research in science, technology, engineering, arts, and mathematics.

Post-vaccination Symptoms with Second Dose of AstraZeneca in a Sample of Immunized Population of Ecuadorian Public Servants

Published date:Nov 09 2023

Journal Title: ESPOCH Congresses: The Ecuadorian Journal of S.T.E.A.M.

Issue title: Volume 3 Issue 1

Pages:780 - 792

DOI: 10.18502/espoch.v3i1.14486

Authors:

TV Carpio Ariastannia.carpio@espoch.edu.ecProfessor in Faculty of Públic Health of the Escuela Superior Politécnica de Chimborazo. Riobamba – Ecuador

RC Saeteros HernándezProfessor in Faculty of Públic Health of the Escuela Superior Politécnica de Chimborazo. Riobamba – Ecuador

P Herrera CisnerosProfessor in Faculty of Públic Health of the Escuela Superior Politécnica de Chimborazo. Riobamba – Ecuador

GR Inca RuizProfessor in Faculty of Públic Health of the Escuela Superior Politécnica de Chimborazo. Riobamba – Ecuador

Abstract:

Since AstraZeneca is a new vaccine against SARSCOV2, it should be monitored worldwide. This study presents the adverse reactions caused by the second dose of the AstraZeneca vaccine. Thequantitative, descriptive, cross-sectional research used a validated survey conducted on 428 public staff who were vaccinated with the second dose of the ChAdOx1-S vaccine at the Escuela Superior Politécnica de Chimborazo, the results were processed in Jamovi. 289 respondents reported having symptoms after inoculation, women (13.15%) presented more symptoms than men (7.27%). Most of the symptoms, both local and systemic, were mild and subsided with the administration of oral analgesics and lasted up to three days in 50% of the cases. AstraZeneca’s vaccine proves to be a safe biologic vaccine to generate antibodies against SARSCOV” in the adult population, and its use is therefore recommended.

Keywords: drug-related side effects and adverse reactions, coronavirus infections, pharmacovigilance

Resumen

Introducción: Dado que se trata de una nueva vacuna contra el SARSCOV2, debe ser monitoreada a nivel mundial, el presente estudio presenta las reacciones adversas presentadas con la segunda dosis de la vacuna AstraZeneca. Materiales y Métodos: La presente investigación cuantitativa, descriptiva, transversal, utilizó una encuesta validada aplicada a 428 funcionarios públicos que fueron vacunados con la segunda dosis de la vacuna ChAdOx1- S en la Escuela Superior Politécnica de Chimborazo, los resultados fueron procesados en Jamovi . Resultados: 289 encuestados informaron tener síntomas después de la inoculación, las mujeres (13,15%) presentaron más síntomas que los hombres (7,27%). La mayoría de los síntomas, tanto locales como sistémicos, fueron leves y cedieron con la administración de analgésicos orales y duraron hasta tres días en el 50% de los casos. Conclusiones: La vacuna de AstraZeneca demuestra ser una vacuna biológica segura para generar anticuerpos frente al SARSCOV” en la población adulta, por lo que se recomienda su uso.

Palabras Clave: kwd2.

References:

[1] Wu Y, Chen C, Chan Y. The outbreak of COVID-19: An overview [Internet]. Journal of the Chinese Medical Association. Wolters Kluwer Health. 2020 [cited 2022 Jun 20];83:217–220. Available from: https://journals.lww.com/jcma/fulltext/2020/03000/ The_outbreak_of_COVID_19__An_overview.3.aspx

[2] Zhou P. Yang Xlou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020 Mar 12 [cited 2022 Jun 20];579(7798):270–273. Available from: https://www.nature.com/articles/s41586-020-2012-7.pdf

[3] Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges [Internet]. International Journal of Antimicrobial Agents. 2020 Mar;55(3):105924. [cited 2022 Jun 20] Available from: https://www.sciencedirect. com/science/article/pii/S0924857920300674?via%3Dihub

[4] Inca-Ruiz P, Inca-León A. Evolution of coronavirus disease (COVID-19) in Ecuador. Science at the Service of Health [Internet]. 2020 Apr 12 [cited 2022 Jun 21];11(1):5– 15. Available from: http://revistas.espoch.edu.ec/index.php/cssn/article/view/441/422

[5] Esparza J, Vizcaino G, Pujol FH. Thrombosis associated with vaccines against Covid-19 based on adenoviral vectors: Implications for vaccination in Venezuela. CientMed [Internet]. 2021 May 21 [cited 2022 Jun 20];2(28):1–7. Available from: https://drive.google.com/file/d/1UtN6T_B2i7sv8fhWC0Q5QTi2c7dwtVI_/view

[6] Cerón G. Vaccines against COVID 19: A short-term view. UTA Medicines [Internet]. 2022 [cited 2022 Jun 20];6(1):1–2. Available from: https://revistas.uta.edu.ec/erevista/index.php/medi/article/view/1556/1307

[7] Pan American Health Organization. Frequently asked questions about vaccines against COVID-19 [Internet]. Washington DC: PAHO/WHO; 2022 [cited 2022 Jun 20]. Available from: https://iris.paho.org/bitstream/handle/10665.2/55751/ OPSFPLIMCOVID19220004_spa.pdf?sequence=5&isAllowed=y

[8] Piebald JJ. Vaccine against COVID-19 [Internet]. Spanish Journal of Chemotherapy. Spanish Society of Chemotherapy; 2021 [cited 2022 Jun 20];34569–598. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638770/

[9] Casas I, Mena G. [The COVID-19 vaccination,Internet]. Medicina Clínica (Barc). 2021 May;156(10):500–502. [cited 2022 Jun 20]

[10] Gaus D. COVID-19: Vaccines. Rural family practice [Internet]. 2021 Mar 29 [cited 2022 Jun 20];6(1). Available from: https://dialnet.unirioja.es/descarga/articulo/7898556.pdf eleven.

[11] 11 Deloria Knoll M, Wonodi C. Comment Oxford-AstraZeneca COVID-19 vaccine efficacy. The Lancet [Internet]. 2021 [cited 2022 Jun 24];397:72–4. Available from:https://pubmed.ncbi.nlm.nih.gov/33306990/

[12] Iacobucci G. Covid-19: Infections fell by 65% after first dose of AstraZeneca or Pfizer vaccine, data show [Internet]. BMJ. 2021 Apr;373(1068):n1068. [cited 2022 Jun 20] Available from: https://www.bmj.com/content/373/bmj.n1068

[13] Ministry of Health. Vaccine sheet against SARS-COV-2 vaccine AZD1222- Astrazeneca Laboratory [Internet]. Santiago de Chile; 2021 Apr [cited 2022 Jun 20]. Available from: https://www.minsal.cl/wp-content/uploads/2021/04/FICHAASTRAZENECA. pdf

[14] Sabillón LM, Reyes OF, Cabrera CA. Frequency of adverse events due to anticovid vaccines in the department of Atlántida, Honduras. Innovare: Science and technology magazine [Internet]. 2021 Dec 15 [cited 2022 Jun 20];10(3):126–130. Available from: https://www.camjol.info/index.php/INNOVARE/article/view/12987/15051 fifteen.

[15] Castelo-Rivas P, Ruiz-Ortega J, Valencia-Pallaroso M. Clinical manifestations post vaccination with AstraZeneca in teachers of the Emilio Lorenzo Stehle Educational Unit Clinical manifestations post vaccination with AstraZeneca in teachers of Emilio Lorenzo Stehle School. [cited 2022 Jun 20]; Available from: http://revistaamc.sld.cu/index.php/amc/article/view/8819

[16] Adelaida S. Vaccination alternatives for children under 60 years of age with a first dose of Astra-Zeneca (05/10/2021 | Policy Commons [Internet]. 2021. Barcelona; 2021 May [cited 2022 Jun 20]. Available from: https://policycommons.net/artifacts/2080343/alternativas-de-vacunacion-paramenores- de-60-anos-con-una-primera-dosis-de-astra-zeneca-10052021/2835641/

[17] Babaee E, Amirkafi A, Tehrani-Banihashemi A. SoleimanvandiAzar N, Eshrati B, Rampisheh Z, et al. Adverse effects following COVID-19 vaccination in Iran. BMC Infectious Diseases [Internet]. 2022 May 18 [cited 2022 Jun 20];22:476. Available from: https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-022-07411- 5.pdf

[18] Lee SW, Moon JY, Lee SK, Lee H, Moon S, Chung SJ, et al. Anti-SARSCoV- 2 Spike Protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19 (AZD1222) vaccine in healthcare workers: Lack of association with age, sex, obesity, and adverse reactions [Internet]. Frontiers in Immunology. 2021 Nov;12(779212):779212. [cited 2022 Jun 20] Available from: https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2932623-4

[19] Rios-González C, Mendez J, Estigarribia G, Aguilar G, Martínez P. Side effects of anti-COVID-19 vaccines in Paraguayan health personnel: An exploratory study. Rev Parag Public Health [Internet]. 2021 [cited 2022 Jun 24];11(2):24–29. Available from:http://scielo.iics.una.py/pdf/rspp/v11n2/2307-3349-rspp-11-02-24.pdf

[20] Leones H, Guzmán C. Vaccination against SARS-COV-2: side effects of the CHADOX1NCOV-19 vaccine (AstraZeneca). Sapienza [Internet]. 2022 Jun 14 [cited 2022 Jun 20];3(3):183–93. Available from:https://journals.sapienzaeditorial.com/index.php/SIJIS/article/view/402/263

[21] Tequare MH, Abraha HE, Adhana MT, Tekle TH, Belayneh EK, Gebresilassie KB, et al. Adverse events of Oxford/AstraZeneca’s COVID-19 vaccine among health care workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia. IJID Regions [Internet]. 2021 Dec [cited 2022 Jun 24];1:124–9. Available from: https: //www.sciencedirect.com/science/article/pii/S2772707621000266

[22] Becker MS, Sofía Becker M, Balbuena C, Samudio M. Post-vaccination adverse reactions and eventual Covid-19 infection in dentists. Revista Ciencias de la Salud [Internet]. 2021 [cited 2022 Jun 20];3(2):85–94. Available from: https://docs.bvsalud. org/biblioref/2021/12/1349330/ao11_vol3n2.pdf

[23] Galván-Casas C, Català A, Muñoz-Santos C. SARS-CoV-2 vaccines and the skin [Internet]. Actas Dermo-Sifiliográficas. 2021 Oct;112(9):828–36. [cited 2022 Jun 20] Available from: https://reader.elsevier.com/reader/sd/pii/S0001731021002039?token= 03D66E252F80E2DD4426BC80CC71C89F47B3BECEDFDAAA74A7FCDD95CCF5DF1A703E194B782392BA0C948AC2D844382F&us-east-1&originCreation=20220621230059

[24] World Health Organization. Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 [Internet]. 2022 Mar [cited 2022 Jun 23]. Available from: https://apps.who.int/iris/bitstream/handle/10665/352467/ WHO-2019-nCoV-vaccines-SAGE-recommendation-AZD1222-annexes-2022. 1-eng.pdf?sequence=1&isAllowed=y

[25] World Health Organization. COVID-19 ChAdOx1-S vaccine [recombinant,Internet]. Geneva; 2021 May [cited 2022 Jun 25]. Available from: https://www.who.int/docs/ default-source/coronaviruse/act-accelerator/covax/21099_spanish_astrazeneca_ vaccine-explainer.pdf?sfvrsn=f7250720_5#:$\sim$:text=ChAdOx1%20nCoV% 2D19%20(Recombinant)%5D&text=The%20vaccine%20ChAdOx1%2DS%2FnCoV, coronavirus%202019%20(COVID%2019).

Cited by
?
PEOPLE’S RESPONSE TO POTENTIAL NATURAL HAZARD-TRIGGERED TECHNOLOGICAL THREATS AFTER A SUDDEN-ONSET EARTHQUAKE IN INDONESIA
F. Lestari et al., INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021
DIFFERENT VANTAGE POINTS AMONGST DIFFERENT STAKEHOLDERS IN NATECH (NATURAL HAZARD-TRIGGERED TECHNOLOGICAL) DISASTERS: A CASE FROM THE 2018 MT. ANAK KRAKATAU ERUPTION AND TSUNAMI
D. Pelupessy et al., IOP CONFERENCE SERIES: EARTH AND ENVIRONMENTAL SCIENCE, 2021
Recommendations
THE ASSOCIATION BETWEEN SERUM RESISTIN LEVEL WITH THE DEGREE OF CORONARY ARTERY STENOSIS
J. Suparyatmo et al., KNE LIFE SCIENCES, 2019
SPIROMETRA IN PTYAS MUCOSUS SNAKE IN SIDOARJO, INDONESIA
Garindra Tiara Pranashinta et al., KNE LIFE SCIENCES, 2017
KNOWLEDGE ABOUT RISK FACTORS FOR CANCER AMONG ADULTS IN NEPAL
Kritika Poudel et al., KNE LIFE SCIENCES, 2018
PERCEIVED FACILITATORS TO PREVENTING PRESSURE ULCER AMONG INTENSIVE CARE UNIT NURSES
Ristina Mirwanti et al., KNE LIFE SCIENCES, 2019
THE EFFECT OF ASSERTIVE TRAINING TOWARDS SELF-ASSERTIVENESS AMONG FEMALE ADOLESCENT OF BULLYING IN JUNIOR HIGH SCHOOL
Desi Sundari Utami et al., KNE LIFE SCIENCES, 2019
Powered by
Download
HTML
Cite
Share
statistics

184 Abstract Views

95 PDF Downloads